GSTM1 and anemia (phenotype): Larger studies of CKD-associated anemia therapy revealed a tendency for CKD progression risk with high Hb goals, according to one meta-analysis; nevertheless, in the total pooled analysis, no difference was seen between higher and lower targets [24].